CN115851497B - Ox bile-resistant bezoar transformation strain and application thereof - Google Patents
Ox bile-resistant bezoar transformation strain and application thereof Download PDFInfo
- Publication number
- CN115851497B CN115851497B CN202211125844.XA CN202211125844A CN115851497B CN 115851497 B CN115851497 B CN 115851497B CN 202211125844 A CN202211125844 A CN 202211125844A CN 115851497 B CN115851497 B CN 115851497B
- Authority
- CN
- China
- Prior art keywords
- bezoar
- bovine
- resistant
- oxgall
- transformation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010004542 Bezoar Diseases 0.000 title claims abstract description 85
- 230000009466 transformation Effects 0.000 title claims abstract description 33
- 210000000941 bile Anatomy 0.000 title claims description 18
- 241000894006 Bacteria Species 0.000 claims abstract description 47
- 241000283690 Bos taurus Species 0.000 claims abstract description 37
- 238000000855 fermentation Methods 0.000 claims abstract description 18
- 230000004151 fermentation Effects 0.000 claims abstract description 18
- 238000000338 in vitro Methods 0.000 claims abstract description 18
- 108020004465 16S ribosomal RNA Proteins 0.000 claims abstract description 15
- 241000588923 Citrobacter Species 0.000 claims abstract description 11
- 230000001580 bacterial effect Effects 0.000 claims description 20
- 239000001963 growth medium Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 235000015278 beef Nutrition 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000012137 tryptone Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 abstract description 57
- 238000006243 chemical reaction Methods 0.000 abstract description 28
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 abstract description 24
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 abstract description 23
- 239000004380 Cholic acid Substances 0.000 abstract description 23
- 229960002471 cholic acid Drugs 0.000 abstract description 23
- 235000019416 cholic acid Nutrition 0.000 abstract description 23
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 abstract description 23
- 238000004519 manufacturing process Methods 0.000 abstract description 12
- 230000003698 anagen phase Effects 0.000 abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 230000018109 developmental process Effects 0.000 abstract description 3
- 230000004083 survival effect Effects 0.000 abstract description 3
- 206010027336 Menstruation delayed Diseases 0.000 abstract 1
- 230000012010 growth Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 5
- 239000003613 bile acid Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 108010048581 Lysine decarboxylase Proteins 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000013095 identification testing Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- LVSQXDHWDCMMRJ-UHFFFAOYSA-N 4-hydroxybutan-2-one Chemical compound CC(=O)CCO LVSQXDHWDCMMRJ-UHFFFAOYSA-N 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- -1 compound bilirubin calcium salt Chemical class 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the field of development and utilization of bovine biliary-resistant bovine bezoar conversion bacteria resources, and particularly relates to a bovine bezoar conversion bacteria resistant to bovine bezoar and application thereof. The characteristic base sequence of the 16S rDNA of the bovine biliary-resistant calculus bovis transformation bacterium is shown as SEQ No.1, and the characteristic base site comprises: 265-A,275-C,280-G,282-A,537-A,581-A, a unique Citrobacter oxgall, strain accession number: CGMCC No.24893 is applied to the fermentation production of in vitro cultured bezoar, and the content of bilirubin and cholic acid is increased by more than 2 times compared with natural oxgall after fermentation for 16 days at 30 ℃. The strain NDZNM-01 can tolerate oxgall with broad-spectrum antibacterial effect, has survival time of more than 9 days in pure oxgall and is in a delayed period within 48 hours, and then enters a logarithmic growth phase to be generally cultured until the cell density reaches a peak value within 96 hours.
Description
Technical Field
The invention belongs to the field of development and utilization of bovine biliary-resistant bovine bezoar conversion bacteria resources, and particularly relates to a bovine bezoar conversion bacteria resistant to bovine bezoar and application thereof.
Background
Because the social demand of natural bezoar is very large and the contradiction between supply and demand is very prominent, in order to solve the contradiction, artificial bezoar is successfully developed in the 50 s of the 20 th century, and the artificial bezoar belongs to formula bezoar, and most cases cannot replace natural bezoar. For this reason, the teaching Cai Gongjiao of the 90 th century was first developed into in vitro cultured bezoar (CN 1022668C, CN1044402A, CN1041105 a) and incorporated into the chinese pharmacopoeia (2020 edition). The in vitro bezoar cultivation is carried out by simulating the formation process of bezoar under pathological conditions, and is formed by co-culturing and transforming ox gall and microorganism, the chemical components and clinical effects of the bezoar are similar to those of natural bezoar, and most of the cases can be equivalent to the use of natural bezoar in medicine and clinical application.
The in vitro cultured bezoar is used as a raw material of Chinese patent medicines and health care products and Chinese medicinal decoction pieces, and has huge market demand space and wide development prospect. At present, only the in vitro cultivation bezoar is produced by the Qingjinshen of Wuhan, and the in vitro cultivation of the production needs to meet the content requirement of the quality detection index of pharmacopoeia by additionally adding a large amount of compound bilirubin calcium salt and bile acid, so that the production cost is high, the market price of the finished product is extremely expensive and exceeds one third of that of natural bezoar, and the biological conversion efficiency of bilirubin and bile acid of the produced strain is also reflected.
The strain is the key for culturing bezoar into yellow in vitro, and not any bacteria can convert oxgall into bezoar; in addition, oxgall has broad-spectrum antibacterial effect, most intestinal bacteria cannot tolerate bile and can not survive in bile for a long time, and particularly, some high-efficiency bezoar transformation bacteria are more difficult to survive in bile for more than 48 hours, so that the bezoar transformation production efficiency is seriously influenced, the production cost is directly determined, and the market price of in-vitro bezoar cultivation is indirectly influenced. Therefore, screening strains which can endure oxgall for a long time and can be efficiently converted into gall-stone is a key for improving the production efficiency of in vitro bezoar cultivation, reducing the production cost, realizing that rare traditional Chinese medicines are not expensive any more and generating common Hui Zhong.
Disclosure of Invention
Aiming at the problems existing in-vitro cultivation of bezoar, the invention screens and obtains a strain of bezoar transformation bacteria resistant to ox bile, researches the bezoar transformation capability and obtains high bezoar transformation efficiency. Improves the production efficiency of in vitro bezoar cultivation, reduces the production cost, and can realize the aim that the rare traditional Chinese medicine bezoar is not expensive any more.
The technical scheme of the invention is as follows:
a strain of bezoar-resistant bacteria is prepared from Citrobacter bovisCitrobacter bovisNDZNM-01, samples of which were deposited at the China general microbiological culture Collection center, accession number: CGMCC No. 24893.
Preferably, the characteristic base sequence of the 16S rDNA of the bezoar transformation bacteria is shown as SEQ No. 1. Preferably, the amplification primer of the characteristic base sequence of the 16S rDNA of the bezoar transformation bacterium is:
the base sequence of the forward F primer is shown as SEQ No. 2; the method comprises the following steps: 5'-CGCAAGCCTGATGCAG-3';
the base sequence of the reverse R primer is shown in SEQ No. 3; the method comprises the following steps: 5'-CTTCGCGTTGCATCGA-3'.
Preferably, the characteristic base site of the 16S rDNA characteristic base sequence of the bezoar transformation bacterium comprises: 265-A,275-C,280-G,282-A,537-A,581-A.
The identification method of the ox gall-resistant bezoar transformation bacteria adopts the amplification primer and controls the characteristic base site.
Further, the bezoar transformation bacteria survive for more than 9 days in pure oxgall.
The invention also aims to protect the application of the ox bile-resistant bezoar transformation bacteria in cultivation production of in-vitro cultivated bezoar.
Further, the fermentation culture conditions of the bezoar transformation bacteria applied to the culture production of in vitro bezoar cultivation are as follows: the pH of the fermentation liquid is 6.5-7.5, and the fermentation temperature is 20-35 ℃.
Further, the culture medium raw materials of the strain expansion culture of the bezoar transformation bacteria applied to the culture production of in vitro bezoar cultivation comprise: tryptone, beef extract, sodium chloride; the semisolid culture medium and the solid culture medium are prepared according to the adding amount of the agar powder.
The invention has the beneficial effects that:
1. high-efficiency conversion of ox bile to form bilirubin and cholic acid as main medicinal components for in vitro culturing bezoar
Strains of the present applicationCitrobacter bovisWhen NDZNM-01 is cultured in oxgall at 30deg.C, the bilirubin and cholic acid content of fermentation 16d respectively reach 2.01%o and 6.42%, bilirubin content is increased by 2.35 times than natural oxgall, and cholic acid content is increased by 2.13 times.
2. Long survival time in oxgall
Because oxgall has broad-spectrum antibacterial effect, most intestinal bacteria are difficult to survive for more than 48 hours in oxgall, and the strain of the applicationCitrobacter bovisNDZNM-01, as measured by growth curve, survives for more than 9 days in pure oxgall, and is a stagnation period within 48 hours when cultured at a fermentation temperature of 30 ℃ in oxgall, then enters a logarithmic growth phase with rapidly increased cell density, and the cell density is maximum when cultured for 96 hours, and then continues to culture for 4 days, and the cell density begins to slowly decrease.
3. The bezoar transformation bacterium of the present applicationCitrobacter bovisNDZNM-01 is a special Citrobacter bovis Seu Bubali-derived from fel bovis Seu Bubali
To date, no document reports that Citrobacter can survive in oxgall, and no document reports that the metabolic activity of Citrobacter can increase the conversion efficiency of bilirubin and cholic acid in oxgall.
Strain preservation information:
preservation time: 2022, 05, 12;
preservation unit: china general microbiological culture Collection center (China Committee for culture Collection);
preservation number: CGMCC No. 24893;
deposit unit address: the institute of microbiology, national institute of sciences, no.3, north chen west way 1, region of korea, beijing city, postal code: 100101;
classification naming: citrobacter oxgallCitrobacter bovis。
Drawings
FIG. 1 is a morphological observation of a bovine bile resistant strain NDZNM-01 and its bezoar transformation performance; a, morphological characteristics of a strain NDZNM-01 resistant to oxgall (magnification 10X 40, scale 50 μm); b, fermenting oxgall-resistant strain NDZNM-01 to form turbid liquid of bezoar particles; c, fermenting the oxgall-resistant strain NDZNM-01 to initiate the process of polymerizing the bezoar particles into bezoar stones; d, fermenting the oxgall-resistant strain NDZNM-01 to initiate the polymerization of the bezoar particles to form bezoar;
FIG. 2 shows the sequencing result of the 16S rDNA amplified fragment of bovine biliary-tolerant transformed strain NDZNM-01;
FIG. 3 is a root system-free phylogenetic tree of 16S rRNA gene segment sequences of bovine biliary powder-resistant transformed strain NDZNM-01 and related strains constructed based on Fast Minimum Evolution method;
FIG. 4 shows the conversion rate of bovine bezoar-resistant bovine bezoar transformant strain NDZNM-01 at different fermented bile pH values;
FIG. 5 shows the effect of culture temperature on the bile-resistant bovine bezoar transformation strain NDZNM-01 cholic acid transformation capacity;
FIG. 6 shows the effect of culture temperature on the ability of bovine biliary-tolerant bovine bezoar transformant strain NDZNM-01 to convert bilirubin;
FIG. 7 shows the growth curve of bovine biliary-resistant transformed strain NDZNM-01.
Detailed Description
EXAMPLE 1 Process for isolation and purification of bovine biliary-tolerant transformed bacteria from bovine bile yellow in the gallbladder
1. Screening media
The formula of the culture medium for screening bezoar transformation bacteria in the oxgall is as follows: 1.00g of tryptone, 0.30g of beef extract and 0.50g of sodium chloride, adding deionized water to a volume of 100ml, heating for dissolving, cooling, adjusting the pH to 7.2, boiling for 10 min, cooling, filtering, packaging, and sterilizing under high pressure for 30 min. 1.5g of agar powder is added when preparing a solid culture medium; 0.3g of agar powder was added when preparing the semisolid culture medium.
2. Bilirubin and cholic acid content determination method
Bilirubin and cholic acid content in oxgall, culture medium and in vitro cultured calculus bovis are detected according to Chinese pharmacopoeia (2020 edition one, medicinal materials and decoction pieces, 181 pages).
3. Process for separating and purifying bezoar transformation bacteria tolerant to oxgall
Fresh oxgall is taken to yellow oxgall, streak culture is carried out on the solid culture medium, after the culture is carried out at the constant temperature of 37 ℃ for 24 h, single colonies with good separation degree are selected and respectively inoculated into the semisolid culture medium, serial numbers are made, after 24 h is cultivated, 100 mu L of bacterial liquid is respectively taken and added into 50 ml sterilized oxgall, after 96h is cultivated, 10 mu L of bacterial liquid is respectively taken and coated on the solid culture medium, after 72 h is cultivated, the number of the colonies is counted, and the colonies with the number of the colonies being more than 1000 are designated as oxgall-resistant strains. The bilirubin and cholic acid content in the oxgall of each cultured tolerant strain was measured, and colonies having bilirubin and cholic acid content in the fermented oxgall of more than 2 times that in the natural oxgall were designated as bezoar transformants.
EXAMPLE 2 morphological observation and physiological Biochemical identification of bovine bile-tolerant transformed bovine bacteria
Example 1 46 single colonies were isolated, cultured in a liquid medium containing 70% oxgall, the culture medium was taken every 1d for cell count and bilirubin and cholic acid content detection, a bile-resistant strain with high comprehensive conversion rate of bilirubin and cholic acid was selected and designated as NDZNM-01, the strain was inoculated on the solid medium of example 1, cultured at 37 ℃ for 24 h, and then the colony morphology was recorded for gram staining and morphological observation.
The purified NDZNM-01 strain was inoculated in the semi-solid medium of example 1, shaking culture was performed at 37℃and 160 rpm for 24 h, 10. Mu.L of the bacterial liquid was inoculated in a bacterial micro biochemical reaction tube, and culture was performed at 37℃for 24. 24 h.about.48. 48h, and physiological biochemical identification tests including gram staining, glucose and sucrose fermentation tests, citrate and nitrate utilization tests, acetylmethyl methanol tests (V.P tests), starch hydrolysis tests, methyl red tests (M.R tests) and extracellular enzyme activity tests (contact enzyme, oxidase, lysine decarboxylase, phenylalanine deaminase) were performed with reference to "Berger's bacteria identification handbook". The results are shown in FIG. 1, and can be seen from FIG. 1: the strain NDZNM-01 forms a gray round colony which is moist, low-convex, smooth in surface, neat in edge and semitransparent on a solid culture medium, is gram-negative, takes a short rod shape under a light microscope, has round two sides, and is periflagellum and sterile hair, and the estimated thallus size is about 2.5 mu m multiplied by 3.5 mu m.
The strain NDZNM-01 is inoculated in a biochemical identification tube for physiological and biochemical identification test, the result is shown in table 1, and gram staining, V.P experiment, starch hydrolysis, sucrose fermentation experiment and the like of the strain NDZNM-01 are negative, glucose, citrate and nitrate are positive by experiment, M.R experiment, contact enzyme detection and the like, and oxidase, lysine decarboxylase, phenylalanine deaminase activity detection and the like are negative. Comparing the detection result with the ' Berger's bacteria identification Manual ', and primarily judging that the strain NDZNM-01 is the bacteria of the genus Citrobacter.
TABLE 1 physiological and biochemical Properties of Strain NDZNM-1
Note that: "+": positive or reactive; "-": negative or no reaction
EXAMPLE 3 molecular identification of bovine bile-tolerant bovine bezoar transformant NDZNM-01
1. Genomic DNA extraction of strain NDZNM-01
The genomic DNA of strain NDZNM-01 was extracted using TIANGEN bacterial genomic DNA extraction kit (DP 302) according to the kit instructions.
2 PCR amplified 16S rDNA of strain NDZNM-01
The BLASTN program is used for carrying out multiple comparison on the enterobacter 16S rDNA sequences recorded in the nr database of GenBank, and a conserved consensus sequence is selected as a PCR amplification primer according to the comparison result.
Forward F primer (16 bp): 5'-CGCAAGCCTGATGCAG-3';
reverse R primer (16 bp): 5'-CTTCGCGTTGCATCGA-3'
3. PCR reaction system for amplifying 16S rDNA of strain NDZNM-01
PCR reaction System (25. Mu.L): 1.0. Mu.L of DNA template, 3.0. Mu.L of 5 XBuffer, 0.5. Mu.L of each of F primer (10. Mu.M) and R primer (10. Mu.M), 1. Mu.L of dNTP (2.50 mM), and ddH 2 O was fixed to a volume of 25. Mu.L. PCR reaction conditions: pre-denaturation at 95 ℃ for 5 min; 95. denaturation at 30S, annealing at 50℃for 30S, elongation at 72℃for 90S, and after 30 cycles, elongation at 72℃for 12min. The amplified product was subjected to agarose gel electrophoresis, and purified and recovered using a TIANGEN (DP 209) agarose gel DNA recovery kit to complete sequencing.
4. 16S rDNA sequence creation system evolution tree using strain NDZNM-01
The BLASTN program was used to search the nr database of GenBank, and homology alignment was performed on the 16S rDNA sequences thus obtained. A phylogenetic tree is constructed by adopting a Fast Minimum Evolution method, and the value of the tree Max Seq Difference is set to be 0.1. Sequence statistical analysis was performed using the edit seq subroutine of DNAStar.
5. Results and conclusions of implementation of the present embodiment
The sequencing results are shown in FIG. 2. The total length of the sequence is 598bp, and the content of C+G is 55.69%. The sequence is as follows: CGCAAGCCTG ATGCAGCCAT GCCGCGTGTA TGAAGAAGGC CTTCGGGTTG TAAAGTACTT TCAGCGAGGA GGAAGGTGTT GTGGTTAATA ACCRCAGCAA TTGACGTTAC TCGCAGAAGA AGCACCGGCT AACTCCGTGC CAGCAGCCGC GGTAATACGG AGGGTGCAAG CGTTAATCGG AATTACTGGG CGTAAAGCGC ACGCAGGCGG TCTGTCAAGT CGGATGTGAA ATCCCCGGGC TCAACCTGGG AACTGCATCC GAAAATGGCA GGCTCGAGTG TAGTAGAGGG GGGTAGAATT CCAGGTGTAG CGGTGAAATG CGTAGAGATC TGGAGGAATA CCGGTGGCGA AGGCGGCCCC CTGGACAAAG ACTGACGCTC AGGTGCGAAA GCGTGGGGAG CAAACAGGAT TAGATACCCT GGTAGTCCAC GCCGTAAACG ATGTCGACTT GGAGGTTGTG CCCTTGAGGC GTGGCTTCCG GAGCTAACGC GTTAAGTCGA CCGCCTGGGG AGTACGGCCG CAAGGTTAAA ACTCAAATGA ATTGACGGGG GCCCGCACAA GCGGTGGAGC ATGTGGTTTA ATTCGATGCA ACGCGAAG.
The rRNA/ITS databases were searched using the BLASTN program (https:// blast. NCBI. Lm. Nih. Gov/blast. Cgi) provided by NCBI (http:// www.ncbi.nlm.nih.gov), and the results showed that the 16S rRNA gene amplified fragment of strain NDZNM-01 had a similarity of greater than 98% to the corresponding sequence of Citrobacter, and that the characteristic base sites included: 265-A,275-C,280-G,282-A,537-A,581-A. The phylogenetic tree was constructed using Fast Minimum Evolution method, and the value of the tree Max Seq Difference was set to 0.7. As can be seen from FIG. 3, the strain NDZNM-01 forms a single line with the other three bacteria of the genus Citrobacter in one branch.
The bacterial strain NDZNM-01 belongs to an intestinal tract bacterium of the genus Citrobacter from oxgall, and is primarily named as the bacterial strain NDZNM-01 of oxgallCitrobacter bovis NDZNM-01 Wang Houwei)。
EXAMPLE 4 detection of bezoar conversion ability of bovine bile-tolerant bovine bezoar conversion bacterium NDZNM-01
1. The method for detecting the bezoar transformation capacity of the bezoar transformation bacteria NDZNM-01 which tolerates the oxgall
According to Chinese pharmacopoeia (2020 edition 1 part), the bezoar conversion ability of the strain NDZNM-01 is expressed in terms of the content of bilirubin and bile acid in fermented oxgall. Bacterial strain NDZNM-01 is inoculated into fresh oxgall respectively, continuous shake culture (120 rpm) is carried out at 37 ℃ for 14d, the same batch of oxgall without inoculating bacterial strain is set as a blank control, the light absorption value of the culture is detected at 560 nm every 1 day, and the content of bilirubin and bile acid is detected.
2. Influence of pH value of oxgall fermentation liquor on bezoar conversion capability of bezoar conversion bacteria NDZNM-01 tolerant to oxgall
Bacterial strain NDZNM-01 is inoculated into semi-solid culture medium of example 1 containing 60% oxgall, cultured for 3d, pH value of oxgall is regulated by citric acid and sodium hydroxide solution, bacterial strain culture solution 5.0 mL is respectively inoculated into 95.0 mL oxgall with pH value of 6.0, 6.5, 7.0, 7.5, 8.0, 8.5 and 9.0, shake culture (120 rpm) is carried out at 37 ℃, after 7 d is cultured, light absorption values of 560 nm are respectively detected, and bilirubin and cholate content in oxgall is detected according to 1.3.1 method.
The results are shown in FIG. 4, where strain NDZNM-01 ferments oxgall at pH7.5 with a bilirubin content of 16.75% (mg.%), with a cholic acid content of 5.16 (g.%) at pH6.5, and unfermented oxgall with a bilirubin content of only 7.14 (mg.%) and a cholic acid content of 2.42 (g.%). Thus, the content of cholic acid and bilirubin in the oxgall fermented by the strain NDZNM-01 is remarkably improved, wherein the content of bilirubin is increased by 2.35 times, and the content of cholic acid is increased by 2.13 times.
As can be seen from FIG. 4, the pH value of oxgall has an inconsistent effect on the conversion rate of cholic acid and bilirubin of the strain NDZNM-01, the conversion rate of bilirubin is high under the slightly alkaline condition, and the conversion rate of cholic acid is high under the slightly acidic condition. The cholic acid content is far beyond the standards of Chinese pharmacopoeia, so the pH value of the fermented oxgall is the principle of conversion of bilirubin. The bezoar transformation efficiency of the strain NDZNM-01 is better that the pH value of fermented bile is 7.2, and too high and too low pH values are not beneficial to bezoar transformation.
3. Influence of oxgall fermentation temperature on the conversion capability of the bezoar conversion strain NDZNM-01 tolerant to oxgall
The strain NDZNM-01 cultured in the semisolid culture medium of example 1 containing 60% bile was inoculated into 95.0 mL fresh oxgall, and cultured under shaking (120 r/min) at 10 ℃, 15 ℃, 20 ℃, 25 ℃, 30 ℃, 35 ℃ and 40 ℃ respectively for 16d, and the cell concentration was detected at 560 nm to detect the bilirubin and bile acid content in oxgall.
The result is shown in FIG. 5, and when the strain NDZNM-01 is cultured at 30 ℃, the content of the cholic acid is the highest until 16d, and reaches 6.42%; fermenting to 14d until the cholic acid conversion efficiency enters a slow growth period when culturing at 25 ℃ and 30 ℃; fermenting to 12d until the cholic acid conversion rate enters a slow growth period when the culture is carried out at 35 ℃ and 40 ℃; at a bile fermentation temperature of 10 ℃, 15 ℃ and 20 ℃, the cholic acid content is positively correlated with the fermentation time, and no slow growth period occurs.
From FIG. 6, it is seen that when the strain NDZNM-01 is cultured at a fermentation temperature of 30 ℃ in oxgall, the bilirubin content reaches 2.01%o up to 16d, and the bilirubin conversion rate enters a slow increasing period when the strain is fermented to 14 d; fermenting to 12d bilirubin conversion rate to slow growth period at 35 ℃ and 40 ℃; at a fermentation temperature of 10 ℃, 15 ℃, 20 ℃, 25 ℃, the bilirubin content is positively correlated with the fermentation time, and no slow growth phase occurs.
Determination of the growth curve of bovine bile-tolerant bovine transformed bacteria NDZNM-01 described in example 5
Inoculating single colony of strain NDZNM-01 into 5 ml semisolid culture medium, shake culturing at 37deg.C for 6 hr, inoculating 1ml of bacterial liquid into 100ml liquid culture medium, shake culturing, and measuring cell density (OD) every 1 day 560 ) At OD 560 Values are on the ordinate and incubation time is on the abscissa to make a growth curve. As shown in FIG. 7, the survival time of the bezoar transformed bacterium NDZNM-01 in the pure oxgall is longer than 9 days, the stagnation period of the bacterial strain NDZNM-01 is within 48 hours, the bacterial strain NDZNM-01 enters a logarithmic growth phase with rapidly-increased bacterial density, the bacterial density is maximum when the bacterial density is cultured for 96 hours, and the bacterial density begins to slowly decrease after the bacterial density is continuously cultured for 4 days.
Claims (9)
1. A strain of bezoar transformation bacteria resistant to ox bile is characterized in that the bezoar transformation bacteria resistant to ox bile is Citrobacter aurantiacaCitrobacter bovis) The sample is preserved in China general microbiological culture Collection center, with the preservation number: CGMCC No. 24893.
2. The bovine biliary tree transformation-resistant bacterium according to claim 1, wherein the characteristic base sequence of 16S rDNA of the bovine tree transformation-resistant bacterium is shown in SEQ ID No. 1.
3. The bovine biliary tree-tolerant transformed bacterium according to claim 1, wherein the amplification primer of the base sequence characteristic of 16S rDNA of the bovine tree-tolerant transformed bacterium is:
the base sequence of the forward F primer is shown as SEQ ID No. 2; the method comprises the following steps: 5'-CGCAAGCCTGATGCAG-3';
the base sequence of the reverse R primer is shown as SEQ ID No. 3; the method comprises the following steps: 5'-CTTCGCGTTGCATCGA-3'.
4. The bovine biliary tree-tolerant transformed bacterium according to claim 2, wherein the characteristic base site of the 16S rDNA characteristic base sequence of the bovine tree-tolerant transformed bacterium is: 265-A,275-C,280-G,282-A,537-A,581-A.
5. The bezoar transformation bacteria of claim 1, wherein the bezoar transformation bacteria survive for a period of time greater than 9d in pure bezoar.
6. The method for identifying bovine biliary powder-resistant transformed bacteria according to any one of claims 1 to 4, wherein the amplification primer according to claim 3 is used to control the characteristic base site according to claim 4.
7. The use of the bovine biliary-resistant bovine bezoar transformant according to claim 1 for culturing bezoar in vitro.
8. The use according to claim 7, wherein the culturing conditions for culturing bezoar outside the bezoar transformed bacteria are: the pH of the fermentation liquid is 6.5-7.5, and the fermentation temperature is 20-35 ℃.
9. The use according to claim 7 or 8, wherein the culture medium materials for the expanded culture of the bacterial species for culturing bezoar in vitro of the bezoar transformation bacteria comprise: tryptone, beef extract, sodium chloride; the semisolid culture medium and the solid culture medium are prepared according to the adding amount of the agar powder.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211125844.XA CN115851497B (en) | 2022-09-16 | 2022-09-16 | Ox bile-resistant bezoar transformation strain and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211125844.XA CN115851497B (en) | 2022-09-16 | 2022-09-16 | Ox bile-resistant bezoar transformation strain and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115851497A CN115851497A (en) | 2023-03-28 |
CN115851497B true CN115851497B (en) | 2024-03-19 |
Family
ID=85660939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211125844.XA Active CN115851497B (en) | 2022-09-16 | 2022-09-16 | Ox bile-resistant bezoar transformation strain and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115851497B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114703109B (en) * | 2022-05-10 | 2023-09-01 | 山东中医药大学 | Bezoar transformation bacteria screening culture medium capable of tolerating oxgall, preparation method and application |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1347700A (en) * | 2001-10-12 | 2002-05-08 | 武汉大鹏药业有限公司 | Method of in vitro culturing medicine ox gallstone with natural ox gall |
CN102512451A (en) * | 2011-12-21 | 2012-06-27 | 武汉健民大鹏药业有限公司 | Method for preparing cattle gall-stone by utilizing fermented oxgall and composite calcium bilirubinate |
CN114703109A (en) * | 2022-05-10 | 2022-07-05 | 山东中医药大学 | Bovine bile-tolerant bezoar transformation bacterium screening culture medium, preparation method and application |
-
2022
- 2022-09-16 CN CN202211125844.XA patent/CN115851497B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1347700A (en) * | 2001-10-12 | 2002-05-08 | 武汉大鹏药业有限公司 | Method of in vitro culturing medicine ox gallstone with natural ox gall |
CN102512451A (en) * | 2011-12-21 | 2012-06-27 | 武汉健民大鹏药业有限公司 | Method for preparing cattle gall-stone by utilizing fermented oxgall and composite calcium bilirubinate |
CN114703109A (en) * | 2022-05-10 | 2022-07-05 | 山东中医药大学 | Bovine bile-tolerant bezoar transformation bacterium screening culture medium, preparation method and application |
Non-Patent Citations (1)
Title |
---|
耐胆汁型牛黄转化菌的分离、鉴定及其牛黄转化活力研究;王厚伟等;《中草药》;20230930;第54卷(第17期);第5742-5747页 * |
Also Published As
Publication number | Publication date |
---|---|
CN115851497A (en) | 2023-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102533588B (en) | Lactobacillus brevis for producing extracellular exopolysaccharide and application thereof | |
CN106754508B (en) | Bacillus subtilis strain and application thereof in soy sauce fermentation and aroma enhancement | |
CN102453689A (en) | Lactobacillus plantarum strain producing extracellular polysaccharide, and application thereof | |
CN103695341B (en) | A kind of algin catenase secreted by marine bacteria and preparation method thereof | |
CN106939288B (en) | Application of lactobacillus plantarum SG5 in production of gamma-aminobutyric acid | |
CN112852664B (en) | Saccharomyces cerevisiae and method for improving yield of gamma-aminobutyric acid produced by saccharomyces cerevisiae | |
CN115851497B (en) | Ox bile-resistant bezoar transformation strain and application thereof | |
CN113403227A (en) | Lactobacillus plantarum and preparation method and application thereof | |
CN108330083A (en) | One plant of streptococcus thermophilus and the application in producing stirred yoghurt | |
CN108018247B (en) | High-yield straight-chain glucan strain and glucan fermentation production method thereof | |
CN106119166B (en) | One plant of Switzerland lactic acid bacteria and its application | |
CN110964760A (en) | Mutagenesis breeding method of high-yield gamma-aminobutyric acid strain | |
CN117511756A (en) | Acid-resistant and oligonitrogen-resistant candida utilis strain capable of producing protein in high yield and application thereof | |
CN117099962A (en) | New application of lactobacillus mucilaginosus LFP fectus001 | |
WO2024021482A1 (en) | Bacillus coagulans capable of stably producing flavor substances of stinky tofu | |
CN116694539A (en) | Lactobacillus plantarum J26 as direct vat set starter, and preparation method and application thereof | |
CN110484477A (en) | One plant of lactobacillus delbrueckii subsp bulgaricus strain and its application | |
CN113957024B (en) | Rhizobium GL-1803 and application thereof in preparation of insoluble beta-glucan | |
CN114015607B (en) | Bacillus amyloliquefaciens for high yield of 5-methyltetrahydrofolic acid and application thereof | |
WO2021218130A1 (en) | Leuconostoc citreum and application thereof in precipitation of starch slurry | |
CN111808763B (en) | Palmatolyis obovatus yeast for producing carotenoid and application thereof | |
CN110438034B (en) | Methane oxidizing bacteria and application thereof | |
CN111117923B (en) | New Laenibacillus aquaticus strain Gj-4 with pectin degrading function | |
CN103468606A (en) | Klebsiella oxytoca and application thereof in allitol production | |
CN111778165A (en) | Aspergillus niger DFY1 and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |